• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Septerna, Inc. - Common Stock (NQ:SEPN)

    30.33 +2.33 (+8.32%)
    Streaming Delayed Price Updated: 3:00 PM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Septerna, Inc. - Common Stock

    News headline image
    Septerna to Present at TD Cowen 46th Annual Health Care Conference
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Participate in 8th Annual Evercore Healthcare Conference
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Participate in Upcoming Investor Conferences
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Participate in Upcoming Investor Conferences
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
    Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers 
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Present at Jefferies Global Healthcare Conference
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    Septerna to Present at TD Cowen 45th Annual Health Care Conference
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
    From Septerna, Inc.
    Via GlobeNewswire
    News headline image
    Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
    From Septerna, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.